• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

News

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News

News · February 4, 2020

La Presse: “Laurent Duvernay-Tardif’s knees at their best thanks to a “knee kinesiography with KneeKG” by EMOVI

emovi kneekg

"Unless he is injured during the game on Sunday, Laurent Duvernay-Tardif will be solid on both knees when he blocks to protect Patrick Mahomes, the Kansas City Chiefs quarterback, in order to allow …

News · November 15, 2019

CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.

centogene

Accelerating new rare disease therapies through collaboration agreement Cambridge, MA, USA & Rostock/Berlin, GERMANY,13 November 2019 – CENTOGENE (Nasdaq: CNTG),commercial-stage company …

News · November 8, 2019

Centogene AG Rings The Nasdaq Stock Market Closing Bell in Celebration of its IPO

…

News · October 29, 2019

CENTOGENE Announces Proposed Initial Public Offering of Common Shares

centogene

October 28, 2019 at 8:53 AM EDT CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare …

News · October 18, 2019

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS

Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient …

News · October 14, 2019

Lilly’s REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval

antibiotics

The approval of REYVOW is significant because it represents the first new class of acute migraine treatment approved by the FDA in more than two decades INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- …

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 5
  • Go to page 6
  • Go to page 7
  • Go to page 8
  • Go to page 9
  • Interim pages omitted …
  • Go to page 51
  • Go to Next Page »

Primary Sidebar

Secondary Sidebar

Additional News

Panthera D-SAD Classic oral appliance now eligible for Medicare reimbursement

August 1, 2022

Kent Imaging Recognized as Most Innovative Medical Imaging Technology Developer in Canada

June 23, 2022

Egg Medical hatches technology to shield health care workers from radiation

March 29, 2022

Egg Medical hatches $13M VC funding

March 15, 2022

Egg Medical, Inc., Closes on $13 million Financing

March 3, 2022

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact